The company is currently in Phase II testing of ZYN002 for treatment of refractory epilepsy and osteoarthritis. It’s also in Phase I testing of ZYN002 for treatment of Fragile X syndrome. ZYN001 is still in preclinical testing for multiple indications as well.
Shares of ZYNE stumbled at the start of 2017 as the company announced a 2.8 million-share offering priced at $18 to raise cash for its research. But after the dip, investors have piled back in on high hopes that the infusion of cash will yield big results.
The risk here isn’t about sales trends or acquisitions at this point, but simply clinical trial data and typical volatility associated with drug approvals. But if you’re looking to play broader medical marijuana trends instead of dissecting federal marijuana laws, ZYNE is a great option – particularly given that its focus on synthetic alternatives may make it more attractive to some consumers or even more effective in its clinical results than naturally grown marijuana
Shares of ZYNE stumbled at the start of 2017 as the company announced a 2.8 million-share offering priced at $18 to raise cash for its research. But after the dip, investors have piled back in on high hopes that the infusion of cash will yield big results.
The risk here isn’t about sales trends or acquisitions at this point, but simply clinical trial data and typical volatility associated with drug approvals. But if you’re looking to play broader medical marijuana trends instead of dissecting federal marijuana laws, ZYNE is a great option – particularly given that its focus on synthetic alternatives may make it more attractive to some consumers or even more effective in its clinical results than naturally grown marijuana